fludarabine,cyclophosphamide,allo-316,allo-647
allogene therapeutics
['allo-316']
icymi: in a clinical trial evaluating 's allo-316, the or rate (orr) was 17% and the disease control rate (dcr) was 89%. #aacr23 read more: 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.